Navigation Links
CYPHER(R) Sirolimus Drug-Eluting Stent Remains Unsurpassed in Terms of Clinical Safety and Efficacy
Date:9/30/2010

results of SORT-OUT IV, comparing Cordis Corporation's CYPHER(R) Sirolimus-eluting Coronary Stent and Abbott's XIENCE V (R) Everolimus-eluting Stent in the primary endpoint of MACE (major acute coronary events) at nine months. These findings were presented the week commencing 20th September 2010 at the TCT Congress, one of the largest cardiovascular industry events held annually in Washington DC. This study adds to the unmatched body of clinical safety and efficacy data on the CYPHER(R) Stent with this comparison to the more recently approved XIENCE V(R) Stent in a contemporary setting.

"The SORT OUT consortium has used CYPHER(R) Stent as the comparator in a number of studies and to date, no newer stent has proven a benefit over CYPHER(R) Stent in terms of clinical safety or efficacy," said Campbell Rogers, M.D., Chief Scientific Officer and Head, Global Research and Development, Cordis Corporation. "The clinical safety and efficacy of the CYPHER(R) Stent in this real-world randomized study reinforce the excellent sustained clinical outcomes consistently seen over the last 10 years."

The large randomized trial SORT OUT IV included more than 2,600 patients across a wide range of lesion and patient complexity. The study was designed to test whether the XIENCE V(R) stent is non-inferior to the CYPHER(R) Stent. Both drug-eluting stents performed better than planned for the composite endpoint of MACE (4.9 % for XIENCE V(R) Stent vs. 5.2% for CYPHER(R) Stent); these data support the non-inferiority of the XIENCE V(R) stent over the CYPHER(R) stent (non-inferiority p=0.01) . There was no statistically significant difference in key markers of safety including the incidence of cardiac death (1.9% for XIENCE V(R) Stent vs. 1.4% for CYPHER(R) Stent: p=0.31), myocardial infarction, (1.1% for XIENCE V(R) Stent vs. 1.4% for CYPHER(R) Stent: p=0.48), or definite or probable stent thrombosis (0.9% for XIENCE V(R) Stent vs. 0.9% for CYPHER(R) Stent: p=0.83).


'/>"/>

SOURCE Cordis Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. CORDIS Announces Results of Ten-Year CYPHER(R) Sirolimus-Eluting Coronary Stent Follow-Up
2. Positive Long Term Data Presented at ACC 2010 Demonstrate Sustained Safety and Efficacy Advantages of the Cypher(R) Sirolimus Drug-Eluting Stent Over the Endeavor(R) Zotarolimus-Eluting Stent
3. OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) has Lower MACE Rate than TAXUS(R) and CYPHER(R) Stents in Clinical Trial
4. Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease
5. Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
6. Two-Year Outcomes From Large Head-to-Head Clinical Trial Indicate Similar Safety Profile in Diabetic Patients for Cypher(R) Sirolimus-Eluting Coronary Stent and Taxus Stent
7. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
8. Patient Enrollment Completed in First Randomized Clinical Study of OrbusNeichs Combo™ Bio-engineered Sirolimus Eluting Stent
9. Pre-clinical Data Show OrbusNeichs Combo Bio-engineered Sirolimus Eluting Stent May Offer Advantages to Current Drug Eluting Stent Technologies
10. MacuSight(TM) Announces Positive Preliminary Results From Phase 1 Study of Sirolimus in Wet Age-Related Macular Degeneration
11. MacuSight(TM) Announces Positive Initial Results From Phase 1 Study of Sirolimus in Diabetic Macular Edema
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... , June 2, 2015 ... defines and segments the concerned market with analysis ... at $261.8 million in 2014, and is estimated ... CAGR of 19.3% from 2014 to 2019. ... Mannequin-Based Simulation Market for an analysis of industry ...
(Date:6/2/2015)... -- Intarcia Therapeutics, Inc. today announced the ... announced synthetic royalty / equity convert financing, bringing the ... Convertible Limited Recourse Notes from Intarcia and are entitled ... future global net sales of ITCA 650 until the ... the option, commencing upon U.S. regulatory approval of ITCA ...
(Date:6/2/2015)... 2015 ANI Pharmaceuticals, Inc. ("ANI") (NASDAQ: ... from the U.S. Food and Drug Administration (FDA) of ... Oral Solution 5mg/5mL. Trailing twelve-month sales for the product ... competitors. ANI expects to begin shipping to its customers ... and CEO of ANI Pharmaceuticals, stated, "This ANDA represents ...
Breaking Medicine Technology:North America Mannequin-Based Simulation Market is Expected to Reach $632.5 Million by 2019, at a CAGR of 19.3% From 2014 to 2019 2North America Mannequin-Based Simulation Market is Expected to Reach $632.5 Million by 2019, at a CAGR of 19.3% From 2014 to 2019 3Intarcia Exercises Re-Opener For Its Recently Closed Royalty / Equity Convert Financing - Raising Total To $300 Million 2Intarcia Exercises Re-Opener For Its Recently Closed Royalty / Equity Convert Financing - Raising Total To $300 Million 3ANI Pharmaceuticals Announces FDA Approval of Oxycodone Hydrochloride Oral Solution 5mg/5mL 2ANI Pharmaceuticals Announces FDA Approval of Oxycodone Hydrochloride Oral Solution 5mg/5mL 3
... YORK, Sept. 15 Otherwise known as ED, ... to obtain or maintain an erection for satisfactory sexual ... the United States and occurs most frequently in men ... heart disease, vascular disease and neurological diseases. However, according ...
... Broadspire, a Crawford Company (NYSE: CRDA ; ... services provider, is proud to announce that Gary Anderberg, Ph.D., ... winner of Risk & Insurance magazine,s 2010 Risk ... as a leader with Broadspire,s e-Triage system, which helps analyze ...
Cached Medicine Technology:Men's Sexual Health and Medical Talk Show Expert Dr. Ridwan Shabsigh, MD Talks About How Erectile Dysfunction Affects Quality of Life 2Men's Sexual Health and Medical Talk Show Expert Dr. Ridwan Shabsigh, MD Talks About How Erectile Dysfunction Affects Quality of Life 3Broadspire's Gary Anderberg Named Risk Innovator of the Year 2Broadspire's Gary Anderberg Named Risk Innovator of the Year 3
(Date:6/2/2015)... 2015 Aidan Booth And Steve ... public yesterday, and has since received rave reviews ... reviewer Tiffany Hendricks has weighed in with her ... course on her website HonestyFirstReviews.com. , "These days ... marketers looking to hone their business skills has ...
(Date:6/2/2015)... 2015 On Wednesday, May 27, 2015, professional ... a top speed of 207.9 mph. In the process, ... break the 200 mph mark. Jay Leno was on ... episode of Jay Leno’s Garage, which will air on CNBC ... 8.5 mile high speed oval at the Continental Tire Proving ...
(Date:6/2/2015)... (PRWEB) June 02, 2015 UCLA Health ... of intent to partner and expand urgent care services ... to approval by the University of California Board of ... transaction will allow UCLA Health to purchase a minority ... Beverly Hills, Calabasas, Newbury Park and Northridge and creates ...
(Date:6/2/2015)... King of Prussia, PA (PRWEB) June 02, 2015 ... Business Process Outsourcing solutions for health plans in the ... announces their participation as a sponsor and exhibitor at ... trade group, America’s Health Insurance Plans. The conference will ... TMG Health exhibition booth, #1303, will offer opportunities for ...
(Date:6/2/2015)... On October 1, 2015 the transition to ICD-10 ... , On Monday, June 1st Congressman Kevin Brady, ... and Means Committee, and 12 members of the Committee ... Services, urging the administration to provide a smooth transition ... is the newest coding system for healthcare professionals to ...
Breaking Medicine News(10 mins):Health News:100K Factory - Review of Aidan Booth and Steve Clayton's New IM System Published 2Health News:774 HP Hennessey Mustang Tested to 207.9 mph 2Health News:UCLA Health Partners With Exer - More Than Urgent Care 2Health News:TMG Health to Sponsor and Exhibit at AHIP’s Institute 2015 2Health News:HomeTown Health Launches a “100 Day Countdown” in Response to ICD-10 Survey 2Health News:HomeTown Health Launches a “100 Day Countdown” in Response to ICD-10 Survey 3Health News:HomeTown Health Launches a “100 Day Countdown” in Response to ICD-10 Survey 4
... even when athletes mistakenly thought they were taking growth ... -- When athletes think they are taking a performance-enhancing ... if they never really take the drug. , So ... received human growth hormone supplements while the other half ...
... US primary care physicians,Novartis earns the highest sales ... Sanofi-Aventis, according to new,research from TNS Healthcare. Novartis ... consistent ability to build strong physician relationships.,Though Pfizer ... has,greater variability in Europe, while Merck,s European performance ...
... ROSWELL, Ga., June 17 Kimberly-Clark Professional is,donating ... Columbus, Ind.,businesses and residents clean up from the ... know that Columbus was hit very hard by ... Barfoot, Vice President of,Kimberly-Clark Professional, North America. "At ...
... June 17 ,Shire Limited (LSE: SHP, Nasdaq: SHPGY), ... of data from a,randomized, long-term safety and tolerability ... (mesalamine). The primary endpoints,of this study were to ... UC patients over 12 months. Data were published ...
... more readily than a commonly used colorectal cancer drug ... but with fewer side effects, MIT researchers have found. ... anticancer agent, but the newly investigated compound, known as ... body tissues from damage. , "This compound, the antitumor ...
... extremely rare condition. There is no definitive treatment for ... intervention, especially endoscopic treatment has recently been used and ... Dr. TH Kim and his colleagues from the Gyeongsang ... the World Journal of Gastroenterology. , Blunt abdominal trauma, ...
Cached Medicine News:Health News:Sports Doping's Effect May Be in the Mind 2Health News:Sports Doping's Effect May Be in the Mind 3Health News:Sports Doping's Effect May Be in the Mind 4Health News:Novartis, Pfizer and Merck Take the Lead on Strong Relationships with Physicians, as Doctors Demand an Expanding Set of Services 2Health News:Novartis, Pfizer and Merck Take the Lead on Strong Relationships with Physicians, as Doctors Demand an Expanding Set of Services 3Health News:Novartis, Pfizer and Merck Take the Lead on Strong Relationships with Physicians, as Doctors Demand an Expanding Set of Services 4Health News:Long-Term Safety Data on Lialda(TM) (mesalamine) for Patients With Ulcerative Colitis Published in Leading GI Journal 2Health News:Long-Term Safety Data on Lialda(TM) (mesalamine) for Patients With Ulcerative Colitis Published in Leading GI Journal 3Health News:Long-Term Safety Data on Lialda(TM) (mesalamine) for Patients With Ulcerative Colitis Published in Leading GI Journal 4Health News:Long-Term Safety Data on Lialda(TM) (mesalamine) for Patients With Ulcerative Colitis Published in Leading GI Journal 5Health News:Long-Term Safety Data on Lialda(TM) (mesalamine) for Patients With Ulcerative Colitis Published in Leading GI Journal 6Health News:MIT researchers see alternative to common colorectal cancer drug 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: